A comprehensive new analysis published in the medical journal JAMA has identified high levels of low-density lipoprotein cholesterol, commonly known as LDL or 'bad' cholesterol, as a major driver of global mortality. In 2023 alone, elevated LDL cholesterol was responsible for 3.6 million deaths worldwide, accounting for 6% of all recorded fatalities that year. The study, which examined data from 204 countries and territories between 1990 and 2023, highlights the persistent and growing threat posed by this cardiovascular risk factor.
LDL cholesterol acts as a fatty substance that accumulates on artery walls, potentially restricting blood flow to the heart and brain. Because this process often occurs silently without immediate pain or warning signs, many individuals remain unaware of their elevated levels until a serious health event, such as a heart attack or stroke, occurs. The research indicates that high LDL levels were the second-leading cause of cardiovascular disease mortality in 2023 and remain among the top ten contributors to death from all causes globally.
While the study notes that age-standardized mortality rates have actually declined since 1990, the absolute number of deaths and years of healthy life lost has risen by approximately 39%. Researchers attribute this trend primarily to the growth and aging of the global population. The burden is not distributed evenly; in 2023, one-third of the global impact of high LDL cholesterol was concentrated in India and China, reflecting shifting health challenges in middle-income nations.
Moving forward, the findings are intended to guide public health strategies for prevention and treatment. Experts emphasize that because high LDL is a modifiable risk factor, better access to diagnostics and effective medications, such as statins, could significantly reduce these preventable deaths. The study serves as a call to action for healthcare systems to prioritize screening and management to address this silent, widespread health crisis.